Reviva Pharmaceuticals Holdings, In... (RVPH)

$0.71

+0.08 (+11.92%)
Rating:
Recommendation:
-
Symbol RVPH
Price $0.71
Beta 0.183
Volume Avg. 0.27M
Market Cap 10.745M
Shares () -
52 Week Range 0.53-4.66
1y Target Est -
DCF Unlevered RVPH DCF ->
DCF Levered RVPH LDCF ->
ROE -51.14% Strong Sell
ROA -59.12% Strong Sell
Operating Margin -
Debt / Equity 18.29% Neutral
P/E -
P/B 0.43 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest RVPH news


Healthcare
Biotechnology
NASDAQ Capital Market

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.